Commentary | Published:

Substantial equivalence: Its uses and abuses

Nature Biotechnology volume 17, pages 10421043 (1999) | Download Citation

Subjects

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , et al. Nature 399, 214 (1999).

  2. 2.

    Nature 398, 98 (1999).

  3. 3.

    , et al. Nature 401, 525–526 (1999).

  4. 4.

    Anon. Recombinant DNA Safety Considerations. Paris: OECD, 1986.

  5. 5.

    Anon. Nature 356, 1– 2 (1992).

  6. 6.

    Field Testing Genetically Modified Organisms: Framework for Decisions. Washington DC: National Academy Press, 1989.

  7. 7.

    Anon. Safety Evaluation of Foods Derived by Modern Biotechnology, Paris: OECD, 1993.

  8. 8.

    Anon. Report of the OECD Workshop on the Toxicological and Nutritional Testing of Novel Foods. SG/ICGB(98) 1, September 1998. Paris: OECD, 1998.

  9. 9.

    Anon. US Food and Drug Administration. Statement of Policy: Foods Derived from New Plant Varieties: Federal Register 57, 22984–23005 (1992).

  10. 10.

    New Scientist,17 April 1999.

Download references

Author information

Affiliations

  1. Henry I. Miller is a senior research fellow at the Hoover Institution, Stanford University, Stanford, CA 94305-6010, miller@hoover.stanford.edu.  He was founding director of the US Food and Drug Administration's Office of Biotechnology, 1989-93 and a member of the OECD Group of Experts on Safety in Biotechnology, 1984-92.

    • Henry I. Miller

Authors

  1. Search for Henry I. Miller in:

About this article

Publication history

Published

DOI

https://doi.org/10.1038/14987

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing